ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GH Guardant Health Inc

18.88
0.30 (1.61%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Guardant Health Inc NASDAQ:GH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.30 1.61% 18.88 18.88 23.50 19.63 18.73 19.11 1,121,543 05:00:04

Guardant Health to Participate in Upcoming June Investor Conferences

20/05/2021 1:05pm

Business Wire


Guardant Health (NASDAQ:GH)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Guardant Health Charts.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the following investor conferences.

  • William Blair 41st Annual Growth Stock Conference Fireside Chat on Tuesday, June 1st at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time
  • Goldman Sachs 42nd Annual Global Healthcare Conference Fireside Chat on Tuesday, June 8th at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time

Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ test for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.

Investor Contact: Carrie Mendivil investors@guardanthealth.com Media Contact: Anna Czene press@guardanthealth.com Julie Johnson julie.johnson@uncappedcommunications.com

1 Year Guardant Health Chart

1 Year Guardant Health Chart

1 Month Guardant Health Chart

1 Month Guardant Health Chart

Your Recent History

Delayed Upgrade Clock